Impact of albumin infusion on prognosis in ICU patients with cirrhosis and AKI: insights from the MIMIC-IV database
Although albumin therapy improved 28-day mortality in some cases, it may also increase mortality in certain subgroups. The use of albumin in critically ill patients with cirrhosis and AKI should be approached with greater consideration of its risks and benefits.
Authors
- Yidi Ge
- You Deng (ORCID: https://orcid.org/0000-0003-0393-1153)
- Jiashuo Li (ORCID: https://orcid.org/0000-0001-6437-689X)
- Jingjing Wang (ORCID: https://orcid.org/0000-0003-4798-8960)
- Mengqi Li (ORCID: https://orcid.org/0000-0003-3894-5651)
- Wenya Chen (ORCID: https://orcid.org/0000-0002-3230-4514)
- Wen Xie (ORCID: https://orcid.org/0000-0002-1033-4720)
Institutions
- Capital Medical University (CN)
- National Clinical Research Center for Digestive Diseases (CN)
- Beijing Friendship Hospital (CN)
- Beijing Ditan Hospital (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2024-10-07
- DOI
- https://doi.org/10.3389/fphar.2024.1467752
- Citations
- 5
- Primary Topic
- Liver Disease and Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 1.85